TEVA PHARMACEUTICAL INDUSTRIES LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value of $19.09 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average intrinsic value for fiscal 2025 was $19.09, a 19.54% increase from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average intrinsic value for fiscal 2024 was $15.97.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $19.09 10-K · filed 2026-02-03 |
| 2024-12-31 | $15.97 10-K · filed 2026-02-03 |